One of the most common procedures in the United States of America is joint replacement surgeries. According to a study that has been conducted, the median age of patients who undergo joint replacement surgery has been decreasing and has been more recurrent on male. A successful surgeon at Bronxcare Health System popularly known as Dr. Ira Kirschenbaum has a deep understanding about the matter for he regularly performs joint replacement surgeries on his patients and works with a number of professional surgeons who also particularize in this area. Dr. Ira Kirschenbaum specializes in complex revision joint replacement surgery, minimally invasive hip and knee replacement, joint reconstruction, and arthroscopy.
Dr. Ira Kirschenbaum currently practices in White Plains, New York. He was able to undergo training in reconstructive surgery and hip and knee replacement at the Rothman Institute in Philadelphia. Before becoming a great expert in the field, he graduated from Albert Einstein College of Medicine where he attained his M.D., and he also studied at Brown University. Dr. Ira Kirschenbaum has been receiving extensive training for knee and hip replacement surgeries for decades, and he is a member of numerous medical associations worldwide. Additionally, he also spends his time writing and lecturing about process management, information technology, and the connection of engineering in his chosen field. Dr. Ira Kirschenbaum takes advantage of technological advancements in improving his services.
Whenever Dr. Ira Kirschenbaum evaluates a patient who is a candidate for hip replacement or knee replacement surgery, he would normally determine whether or not the surgery that he will be performing will offer a considerable or significant improvement to the quality of life of the patient. There are instances where he recommends other treatments when it comes to helping a patient such as maintaining a proper diet, exercising, switching habits and daily activities.
Read more about Dr. Ira in an interview he gave recently https://interview.net/dr-ira-kirschenbaum/
Amicus Therapeutics, Inc. is a leading new frontier global biotechnology company based in Cranbury, New Jersey. This innovative company researches new discovery findings, the development, and adopting therapies for devastating rare and orphan diseases. Amicus Therapeutics has a vigorous line of one-of-a-kind small molecules called ‘pharmacological chaperones.’ The chaperones provide dual-treatment to bind, stabilize and increase the activity of a patient’s own deformed enzymes to potentially improve enzyme replacement therapy outcome.
Amicus Therapeutics, Inc., research and development processes began as a result of Megan Crowley, who was diagnosed with Pompe disease which she had been suffering with since the age of one. Pompe is a progressive muscle and respiratory weakening disease with a high mortality rate. Megan’s father, John Crowley is now the CEO of this biotechnology company which has a pipeline of therapies for human genetic diseases like his daughter has. Mr. Crowley is determined to find a cure for his daughter and many others who suffer from rare, unexplored diseases (https://www.glassdoor.com/Reviews/Amicus-Therapeutics-Reviews-E26068.htm). His quest has made Amicus Therapeutics a leader for the drug industry and has made them champions in the development of new medical treatments and programs.
Fabry is also an early age disease that affects millions around the world, just like the Pompe disease. Fabry disease leads to progressive, irreversible organ damage, typically involving the nervous, cardiac, and renal systems, as well as multiple other tissues. Both diseases require daily medical assistance to manage and control the complications of these devastating diseases affecting multiple organ systems. To find a cure for the Fabry disease, the Pompe disease, and other chronic diseases, Amicus Therapeutics is investigating enzyme replacement therapy, influencing chaperone advanced replacement therapy, taking a lead in the clinical development of topical medicine to treat genetic connective tissue disorders, including investigating many other scientific first treatments and discovery programs.
Amicus Therapeutics is leading the fight in developing a topical therapy for the treatment of lesions and blisters that appear on the skin and in some cases on the lining of other body organs. This rare, chronic disease is known as Epidermolysis Bullosa. Epidermolysis Bullosa can potentially become disfiguring, and in some cases fatal. Amicus Therapeutics has also taken the lead recently in promising finds for the underlying cause of muscle damage and weakness in Pompe patients. This pioneering company has a three-fold promise, which is to remain at the forefront of therapies for rare and orphan diseases, to build long-term value for stakeholders and to foster teamwork and respect for each individual’s contribution.